Despite these challenges, biologics offer unique advantages for targeting extracellular protein aggregates, modulating cell surface receptors, and engaging immune mechanisms relevant to Alzheimer’s disease pathogenesis. Here, CD177 is linked to early-onset autosomal dominant Alzheimer disease.